<DOC>
	<DOCNO>NCT01187953</DOCNO>
	<brief_summary>This study evaluate efficacy safety LCP-Tacro ( tacrolimus ) Tablets administer once-a-day compare Prograf ( tacrolimus ) Capsules twice-a-day immunosuppression prevention organ rejection newly transplant adult kidney transplant recipient . Patients treat 12 month study period follow 12 month , blind extension treatment period To show LCP-Tacro Tablets clinically similar Prograf Capsules prevention acute rejection .</brief_summary>
	<brief_title>Double-Blind , Double-Dummy , Efficacy/Safety , LCP-Tacro™ Vs Prograf® , Prevention Rejection , De Novo Adult Kidney Tx</brief_title>
	<detailed_description>This two-armed parallel group , prospective , randomize , double-blind , double-dummy , multicenter Phase 3 clinical study establish efficacy safety LCP-Tacro Tablets ( tacrolimus , LifeCycle Pharma A/S , Hørsholm , Denmark ) daily prevention allograft rejection de novo adult male female recipient primary secondary kidney transplant evaluate combined efficacy endpoint comprise acute rejection , graft loss patient loss . The trial design determine test drug , LCP-Tacro , inferior unacceptable extent reference compound , Prograf . Recipients kidney transplant sign inform consent form fulfill inclusion exclusion criterion randomly assign once-daily therapy LCP-Tacro Tablets twice-daily therapy Prograf Capsules ( tacrolimus , Astellas Pharma US , Inc. , Deerfield , IL ) , concomitantly administer mycophenolate mofetil ( MMF ) corticosteroid . All patient also receive interleukin-2 ( IL-2 ) receptor antagonist ( e.g. , Simulect® , basiliximab ; Novartis Pharmaceuticals , East Hanover , NJ ) . Following screening , transplantation , randomization , study visit conduct 12-month treatment period ; additional visit 12 month extension period treatment follow-up safety assessment visit telephone interview 30 day withdrawal study drug .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1. informed consent 2 . 18 70 year , inclusive 3. receive primary secondary renal allograft decease donor nonhuman leukocyte antigen ( HLA ) identical living donor 4. know contraindication administration IL2 receptor antagonist induction therapy , MMF , corticosteroid tacrolimus 5. negative pregnancy test 6 . Negative cross match test , compatible ( A , B , AB O ) blood type 7 . Able swallow tablet capsule 1 . Recipients nonrenal transplant ( solid organ bone marrow ) ever 2 . Panel reactive antibody ( PRA ) &gt; 30 % 3 . Patients condition may affect study drug absorption ( e.g . gastrectomy clinically significant diabetic gastroenteropathy ) 4 . Body mass index ( BMI ) 18 kg/m2 5 . History alcohol abuse 6 . History recreational drug abuse 7 . Screening 12lead electrocardiogram ( ECG ) demonstrate clinically relevant abnormality 8 . WOCBP either pregnant , lactating , plan become pregnant 9 . Patients oral temperature ( prior study drug dose ) 38.0 ºC ( 100.4 ºF ) high 10 . Patients clinically significant active infection 11 . Patients know hereditary immunodeficiency 12 . Patients malignancy history malignancy ( within last 5 year ) 13 . Patients receive expect receive sirolimus , everolimus , azathioprine , cyclophosphamide within 3 month prior enrollment 14 . Patients evidence clinically significant disease ( e.g. , cardiac , gastrointestinal hepatic disorder ) 15 . Patients reversible cardiac ischemia ( history untreated reversible ischemia stress test ) 16 . Patients clinically symptomatic congestive heart failure document ejection fraction le 45 % 17 . Patients significant chronic obstructive pulmonary disease , pulmonary restrictive disease significant pulmonary hypertension 18 . Treatment investigational drug , device regimen within 1 year precede first dose study drug 19 . Patients unwilling refrain consumption grapefruit grapefruit contain juice 20 . Patients receive concomitant drug may affect concentration tacrolimus whole blood , list Appendix 2 21 . Laboratory variable abnormal ( outside laboratory reference range ) clinically relevant , judge Investigator 22 . Patients positive result follow serological test : human immunodeficiency virus ( HIV ) 1 antibody , hepatitis B virus ( HBV ) surface antigen ( HBsAg ) , antihepatitis B core antibody ( HBcAb ) , antihepatitis C virus ( HCV ) antibody ( HCV Ab ) . 23 . Patients experience graft loss within 1 year transplant , due acute rejection due BK nephropathy 24 . Patients experience focal segmental glomerulosclerosis ( FSGS ) 25 . Donor positive serological test result HIV1 , HBV HCV 26 . Donor history malignant disease ( current historical ) 27 . Centers Disease Control Prevention highrisk donor 28 . Patients mental dysfunction inability cooperate study 29 . Cold ischemia time &gt; 30 hour 29 . Nonheartbeating donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Acute Rejection</keyword>
	<keyword>Kidney</keyword>
</DOC>